GE Healthcare has announced plans to install its second FlexFactory manufacturing platform for cell therapy, this time at Xiangxue Pharmaceutical’s site in Guangzhou, China.
GE Healthcare Life Sciences is expanding powdered cell culture media production in Austria and the US, where it says longer shelf-life and reduced transport costs are driving demand.
Fluid distribution and warehouse management challenges are among the ‘pitfalls’ of the single-use biopharmaceutical facility, says Avid Bioservices executive.
Berkeley Lights has signed a new agreement with Sanofi through which the company will use its Beacon OptoFluidic Platform to fast-track cell line development.
GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.
A new vaccine manufacturing facility in Toronto, Canada will boast single-use tech and closed continuous process to help improve productivity and performance, Sanofi says.
Demand for a protein produced from a marine mollusk used as a carrier molecule in therapeutic vaccines has driven Stellar Biotech to expand a facility in LA.
Vendors can help address technology gaps but industry must look to collaborations and internal development to create fully continuous bioprocesses, says MilliporeSigma.
“We need Big Pharma and we are getting Big Pharma,” says Dyadic
Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.
